SG11201610226SA - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators - Google Patents
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activatorsInfo
- Publication number
- SG11201610226SA SG11201610226SA SG11201610226SA SG11201610226SA SG11201610226SA SG 11201610226S A SG11201610226S A SG 11201610226SA SG 11201610226S A SG11201610226S A SG 11201610226SA SG 11201610226S A SG11201610226S A SG 11201610226SA SG 11201610226S A SG11201610226S A SG 11201610226SA
- Authority
- SG
- Singapore
- Prior art keywords
- indane
- guanylate cyclase
- soluble guanylate
- indoline derivatives
- cyclase activators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020166P | 2014-07-02 | 2014-07-02 | |
| US201562168627P | 2015-05-29 | 2015-05-29 | |
| PCT/IB2015/055006 WO2016001875A1 (en) | 2014-07-02 | 2015-07-02 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610226SA true SG11201610226SA (en) | 2017-01-27 |
Family
ID=53724402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610226SA SG11201610226SA (en) | 2014-07-02 | 2015-07-02 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10208018B2 (en) |
| EP (1) | EP3164395B1 (en) |
| JP (1) | JP2017519835A (en) |
| KR (1) | KR20170021345A (en) |
| CN (1) | CN106470985A (en) |
| AP (1) | AP2016009609A0 (en) |
| AU (1) | AU2015283617B2 (en) |
| BR (1) | BR112016030733A2 (en) |
| CA (1) | CA2953885A1 (en) |
| CL (1) | CL2016003329A1 (en) |
| CO (1) | CO2017000222A2 (en) |
| CR (1) | CR20170003A (en) |
| CU (1) | CU20160192A7 (en) |
| EA (1) | EA030634B1 (en) |
| EC (1) | ECSP17007208A (en) |
| ES (1) | ES2732758T3 (en) |
| GT (1) | GT201600269A (en) |
| IL (1) | IL249406A0 (en) |
| MX (1) | MX2016017325A (en) |
| PE (1) | PE20170323A1 (en) |
| PH (1) | PH12016502539A1 (en) |
| SG (1) | SG11201610226SA (en) |
| SV (1) | SV2016005351A (en) |
| TN (1) | TN2016000556A1 (en) |
| TW (1) | TW201625584A (en) |
| WO (1) | WO2016001875A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201625584A (en) | 2014-07-02 | 2016-07-16 | 諾華公司 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2017103888A1 (en) * | 2015-12-18 | 2017-06-22 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
| WO2017201683A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
| RU2019104002A (en) * | 2016-07-22 | 2020-08-24 | Тоа Эйо Лтд. | THERAPEUTIC AGENT FOR GLAUCOMA |
| WO2018069148A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Use of activators and stimulators of sgc comprising a beta2 subunit |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| TW202015676A (en) | 2018-05-15 | 2020-05-01 | 德商拜耳廠股份有限公司 | Use of 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| CN112566670A (en) | 2018-08-06 | 2021-03-26 | 尼科斯股份有限公司 | Nitric oxide releasing phosphodiesterase type 5 inhibitors |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332943C (en) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use pharmaceutical preparations comprising them |
| EP1420023B1 (en) | 2001-01-24 | 2006-12-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Use of fused pyrazolyl compounds for the preparation of a medicament for treating hypertension |
| DE10110749A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituted aminodicarboxylic acid derivatives |
| DE10110750A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
| DE10216145A1 (en) | 2002-04-12 | 2003-10-23 | Bayer Ag | Use of stimulators of soluble guanylate cyclase to produce a medicament for treating glaucoma |
| JP2007524596A (en) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | Co-crystal pharmaceutical composition |
| JP2010512328A (en) * | 2006-12-11 | 2010-04-22 | レビバ ファーマシューティカルズ，インコーポレーテッド | Composition, synthesis and method of use of indanone cholinesterase inhibitors |
| DE102007015035A1 (en) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituted dibenzoic acid derivatives and their use |
| WO2009032248A1 (en) | 2007-08-31 | 2009-03-12 | Kalsi Engineering, Inc. | Rotary seal with improved film distribution |
| WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| TW200938529A (en) | 2007-12-03 | 2009-09-16 | Smithkline Beecham Corp | Compounds |
| JP5432890B2 (en) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | Heterocyclic derivatives and uses thereof |
| DE102008018675A1 (en) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclic substituted carboxylic acid derivatives and their use |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| JP5411300B2 (en) * | 2009-02-26 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Soluble guanylate cyclase activator |
| DE102009012314A1 (en) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclic substituted alkylcarboxylic acids and their use |
| DE102009046115A1 (en) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted 3-phenylpropanoic acids and their use |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| ES2548394T3 (en) | 2010-02-05 | 2015-10-16 | Adverio Pharma Gmbh | GCs stimulators or GCs activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis |
| ME02207B (en) | 2010-05-26 | 2016-02-20 | Adverio Pharma Gmbh | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS |
| US20130158028A1 (en) | 2010-06-25 | 2013-06-20 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| KR20130136504A (en) | 2010-12-07 | 2013-12-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| GEP20176631B (en) | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| JP5565645B1 (en) | 2012-10-09 | 2014-08-06 | Ｄｉｃ株式会社 | Bump cushion |
| US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
| US20160214956A1 (en) | 2013-09-05 | 2016-07-28 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| TW201625584A (en) | 2014-07-02 | 2016-07-16 | 諾華公司 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators |
| TW201625601A (en) | 2014-07-02 | 2016-07-16 | 諾華公司 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
| TW201625586A (en) | 2014-07-02 | 2016-07-16 | 諾華公司 | Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
-
2015
- 2015-07-01 TW TW104121398A patent/TW201625584A/en unknown
- 2015-07-02 WO PCT/IB2015/055006 patent/WO2016001875A1/en active Application Filing
- 2015-07-02 KR KR1020177002515A patent/KR20170021345A/en unknown
- 2015-07-02 CR CR20170003A patent/CR20170003A/en unknown
- 2015-07-02 BR BR112016030733A patent/BR112016030733A2/en not_active Application Discontinuation
- 2015-07-02 US US15/320,810 patent/US10208018B2/en active Active
- 2015-07-02 CA CA2953885A patent/CA2953885A1/en not_active Abandoned
- 2015-07-02 MX MX2016017325A patent/MX2016017325A/en unknown
- 2015-07-02 PE PE2016002818A patent/PE20170323A1/en unknown
- 2015-07-02 AU AU2015283617A patent/AU2015283617B2/en not_active Ceased
- 2015-07-02 EP EP15742103.3A patent/EP3164395B1/en active Active
- 2015-07-02 SG SG11201610226SA patent/SG11201610226SA/en unknown
- 2015-07-02 EA EA201692542A patent/EA030634B1/en not_active IP Right Cessation
- 2015-07-02 AP AP2016009609A patent/AP2016009609A0/en unknown
- 2015-07-02 TN TN2016000556A patent/TN2016000556A1/en unknown
- 2015-07-02 ES ES15742103T patent/ES2732758T3/en active Active
- 2015-07-02 JP JP2017520035A patent/JP2017519835A/en not_active Ceased
- 2015-07-02 CN CN201580036394.9A patent/CN106470985A/en active Pending
-
2016
- 2016-12-06 IL IL249406A patent/IL249406A0/en unknown
- 2016-12-19 PH PH12016502539A patent/PH12016502539A1/en unknown
- 2016-12-22 SV SV2016005351A patent/SV2016005351A/en unknown
- 2016-12-23 GT GT201600269A patent/GT201600269A/en unknown
- 2016-12-26 CL CL2016003329A patent/CL2016003329A1/en unknown
- 2016-12-28 CU CUP2016000192A patent/CU20160192A7/en unknown
-
2017
- 2017-01-11 CO CONC2017/0000222A patent/CO2017000222A2/en unknown
- 2017-02-02 EC ECIEPI20177208A patent/ECSP17007208A/en unknown
-
2018
- 2018-12-11 US US16/216,420 patent/US10550102B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2953885A1 (en) | 2016-01-07 |
| IL249406A0 (en) | 2017-02-28 |
| EA201692542A1 (en) | 2017-04-28 |
| US20170197940A1 (en) | 2017-07-13 |
| EP3164395B1 (en) | 2019-03-27 |
| PH12016502539A1 (en) | 2017-04-10 |
| EP3164395A1 (en) | 2017-05-10 |
| ES2732758T3 (en) | 2019-11-25 |
| CL2016003329A1 (en) | 2017-06-09 |
| CO2017000222A2 (en) | 2017-05-19 |
| EA030634B1 (en) | 2018-09-28 |
| WO2016001875A1 (en) | 2016-01-07 |
| GT201600269A (en) | 2018-12-18 |
| ECSP17007208A (en) | 2018-09-30 |
| TN2016000556A1 (en) | 2018-04-04 |
| SV2016005351A (en) | 2018-08-20 |
| US10550102B2 (en) | 2020-02-04 |
| AP2016009609A0 (en) | 2016-12-31 |
| KR20170021345A (en) | 2017-02-27 |
| TW201625584A (en) | 2016-07-16 |
| MX2016017325A (en) | 2017-05-01 |
| AU2015283617B2 (en) | 2017-10-05 |
| CN106470985A (en) | 2017-03-01 |
| US10208018B2 (en) | 2019-02-19 |
| US20190119254A1 (en) | 2019-04-25 |
| CU20160192A7 (en) | 2017-04-05 |
| PE20170323A1 (en) | 2017-04-21 |
| AU2015283617A1 (en) | 2017-01-12 |
| JP2017519835A (en) | 2017-07-20 |
| CR20170003A (en) | 2017-03-10 |
| BR112016030733A2 (en) | 2017-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249406A0 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| HRP20181742T1 (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
| EP3152214A4 (en) | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators | |
| HK1244813A1 (en) | Nulceoside phosphoroamidate esters and derivatives thereof, use and synthesis thereof | |
| HK1254654A1 (en) | 4,6-pyrimidinylene derivatives and uses thereof | |
| ZA201701835B (en) | Novel soluble guanylate cyclase activators and their use | |
| PT3215147T (en) | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | |
| EP3079701A4 (en) | Soluble guanylate cyclase activators | |
| EP3079700A4 (en) | Soluble guanylate cyclase activators | |
| EP3099171A4 (en) | Dihydropteridinone derivatives and uses thereof | |
| IL252757A0 (en) | Workbench and articles associates therewith | |
| EP3154972A4 (en) | Azamophinan derivatives and use thereof | |
| EP3310782A4 (en) | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | |
| EP3303342A4 (en) | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators | |
| HK1246156B (en) | Fgf21 derivatives and uses thereof | |
| HK1254636A1 (en) | Indane derivatives and the use thereof as soluble guanylate cyclase activators | |
| EP3177147A4 (en) | Dihydropteridinone derivatives and uses thereof | |
| HRP20182050T8 (en) | Water-soluble taxane derivatives and uses thereof | |
| PT3157912T (en) | Parasiticidal compositions comprising indole derivatives, methods and uses thereof | |
| IL249122A0 (en) | Imidazol- or 1,2,4-triazol-derivatives and their use | |
| PL3386988T3 (en) | Novel dihydropyranopyrimidinone derivatives, and use thereof | |
| EP3227293A4 (en) | 6.7-cyclicmorphinan derivatives and use thereof | |
| PL3166945T3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| EP3166946A4 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |